Omeprazole

Generic Name
Omeprazole
Brand Names
Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
Drug Type
Small Molecule
Chemical Formula
C17H19N3O3S
CAS Number
73590-58-6
Unique Ingredient Identifier
KG60484QX9
Background

Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...

Indication

Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:

• Treatment of active duodenal ulcer in adults

• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer

recurrence in adults

• Treatment of active benign gastric ulcer in adults
...

Associated Conditions
Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
Associated Therapies
-
Clinical Trials
Related News
prnewswire.com
·

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization

Medi-Cal and RedHill renew contract to maintain Talicia's first-line position on the Medi-Cal Fee-For-Service (FFS) Contract Drug List (CDL) with no prior authorization and a $0 copay, benefiting 15 million Californian Medi-Cal patients. The renewal reflects both parties' commitment to improving patient access and outcomes, aligning with the new American College of Gastroenterology (ACG) Clinical Guideline for H. pylori infection, which lists Talicia as an empirically prescribed first-line option.
prnewswire.com
·

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

New U.S. patent issued for a novel coronavirus pneumonia biomarker (≤60% FiO₂) prognostic for opaganib's potential efficacy in treating COVID-19. Post-hoc data from opaganib's Phase 2/3 study showed better outcomes in patients with ≤60% FiO₂ levels, including reduced need for supplemental oxygen, intubation/mechanical ventilation, and mortality.
pharmacydaily.com.au
·

Stomach drugs' class action

Patients using PPIs for digestive issues, who developed gastric cancer or kidney damage, can register for a class action by Shine Lawyers. Drugs under investigation include Nexium, Losec, Somac, Pariet, and Zoton FasTabs. PPIs reduce stomach acid but may increase gastrin levels linked to cancer cell formation.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy